Re-re-treatment of hepatitis C virus

Eight patients who relapsed twice after direct-acting-antiviral drugs

Joshua Hartman, Kian Bichoupan, Neal Patel, Sweta Chekuri, Alyson Harty, Douglas Dieterich, Ponni Perumalswami, Andrea D. Branch

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

AIM: To determine risk factors associated with hepatitis C virus (HCV) treatment failure after direct acting antivirals in patients with complex treatment histories. METHODS: All HCV mono-infected patients who received treatment at our institution were queried. Analysis was restricted to patients who previously failed treatment with boceprevir (BOC) or telaprevir (TVR) and started simeprevir (SMV) and sofosbuvir (SOF) ± ribavirin (RBV) between December 2013 and June 2014. Patients with human immunodeficiency virus (HIV)/HCV co-infection or patients who received a liver transplant in the past were excluded. Viral loads were recorded while on treatment and after treatment. Data collection continued until December, 31st 2014 when data analysis was initiated. Patients missing virologic outcomes data were not included in the analysis. Analysis of 35 patients who had virologic outcome data available resulted in eight patients who were viral load negative at the end of treatment with SMF/SOF but later relapsed. Data related to patient demographics, HCV infection, and treatment history was collected in order to identify risk factors shared among patients who failed treatment with SMF/SOF. RESULTS: Eight patients who were treated with the first generation HCV protease inhibitors BOC or TVR in combination with pegylated-interferon (PEG) and RBV who failed this triple therapy were subsequently retreated with an off-label all-oral regimen of SMV and SOF for 12 wk, with RBV in seven cases. Treatment was initiated before the Food and Drug Administration approved a 24-wk SMV/SOF regimen for patients with liver cirrhosis. All eight patients had an end of treatment response, but later relapsed. Eight (100%) patients were male. Mean age was 56 (range, 49-64). Eight (100%) patients had previously failed PEG/ RBV dual therapy at least once in addition to prior failure with triple therapy. Total number of times treated ranged from 3-6 (mean 3.8). Eight (100%) patients were male had liver cirrhosis as determined by Fibroscan or MRI. Seven (87.5%) patients had genotype 1a HCV. Seven (87.5%) patients had over 1 million IU/mL HCV RNA at the time of re-treatment. CONCLUSION: This study identifies factors associated with SMV/SOF treatment failure and provides evidence that twleve weeks of SMV/SOF/RBV is insufficient in cirrhotics with high-titer genotype 1a HCV.

Original languageEnglish (US)
Pages (from-to)12430-12438
Number of pages9
JournalWorld Journal of Gastroenterology
Volume21
Issue number43
DOIs
StatePublished - Nov 21 2015
Externally publishedYes

Fingerprint

Hepacivirus
Antiviral Agents
Ribavirin
Therapeutics
Virus Diseases
Viral Load
Treatment Failure
Liver Cirrhosis
Interferons
Genotype
United States Food and Drug Administration
Sofosbuvir
Protease Inhibitors
Coinfection

Keywords

  • Hepatitis c
  • Protease inhibitor
  • Relapse
  • Simeprevir
  • Sofosbuvir
  • Treatment failure

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Re-re-treatment of hepatitis C virus : Eight patients who relapsed twice after direct-acting-antiviral drugs. / Hartman, Joshua; Bichoupan, Kian; Patel, Neal; Chekuri, Sweta; Harty, Alyson; Dieterich, Douglas; Perumalswami, Ponni; Branch, Andrea D.

In: World Journal of Gastroenterology, Vol. 21, No. 43, 21.11.2015, p. 12430-12438.

Research output: Contribution to journalArticle

Hartman, J, Bichoupan, K, Patel, N, Chekuri, S, Harty, A, Dieterich, D, Perumalswami, P & Branch, AD 2015, 'Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs', World Journal of Gastroenterology, vol. 21, no. 43, pp. 12430-12438. https://doi.org/10.3748/wjg.v21.i43.12430
Hartman, Joshua ; Bichoupan, Kian ; Patel, Neal ; Chekuri, Sweta ; Harty, Alyson ; Dieterich, Douglas ; Perumalswami, Ponni ; Branch, Andrea D. / Re-re-treatment of hepatitis C virus : Eight patients who relapsed twice after direct-acting-antiviral drugs. In: World Journal of Gastroenterology. 2015 ; Vol. 21, No. 43. pp. 12430-12438.
@article{fc6eba85052f4c17adb72383fe782abc,
title = "Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs",
abstract = "AIM: To determine risk factors associated with hepatitis C virus (HCV) treatment failure after direct acting antivirals in patients with complex treatment histories. METHODS: All HCV mono-infected patients who received treatment at our institution were queried. Analysis was restricted to patients who previously failed treatment with boceprevir (BOC) or telaprevir (TVR) and started simeprevir (SMV) and sofosbuvir (SOF) ± ribavirin (RBV) between December 2013 and June 2014. Patients with human immunodeficiency virus (HIV)/HCV co-infection or patients who received a liver transplant in the past were excluded. Viral loads were recorded while on treatment and after treatment. Data collection continued until December, 31st 2014 when data analysis was initiated. Patients missing virologic outcomes data were not included in the analysis. Analysis of 35 patients who had virologic outcome data available resulted in eight patients who were viral load negative at the end of treatment with SMF/SOF but later relapsed. Data related to patient demographics, HCV infection, and treatment history was collected in order to identify risk factors shared among patients who failed treatment with SMF/SOF. RESULTS: Eight patients who were treated with the first generation HCV protease inhibitors BOC or TVR in combination with pegylated-interferon (PEG) and RBV who failed this triple therapy were subsequently retreated with an off-label all-oral regimen of SMV and SOF for 12 wk, with RBV in seven cases. Treatment was initiated before the Food and Drug Administration approved a 24-wk SMV/SOF regimen for patients with liver cirrhosis. All eight patients had an end of treatment response, but later relapsed. Eight (100{\%}) patients were male. Mean age was 56 (range, 49-64). Eight (100{\%}) patients had previously failed PEG/ RBV dual therapy at least once in addition to prior failure with triple therapy. Total number of times treated ranged from 3-6 (mean 3.8). Eight (100{\%}) patients were male had liver cirrhosis as determined by Fibroscan or MRI. Seven (87.5{\%}) patients had genotype 1a HCV. Seven (87.5{\%}) patients had over 1 million IU/mL HCV RNA at the time of re-treatment. CONCLUSION: This study identifies factors associated with SMV/SOF treatment failure and provides evidence that twleve weeks of SMV/SOF/RBV is insufficient in cirrhotics with high-titer genotype 1a HCV.",
keywords = "Hepatitis c, Protease inhibitor, Relapse, Simeprevir, Sofosbuvir, Treatment failure",
author = "Joshua Hartman and Kian Bichoupan and Neal Patel and Sweta Chekuri and Alyson Harty and Douglas Dieterich and Ponni Perumalswami and Branch, {Andrea D.}",
year = "2015",
month = "11",
day = "21",
doi = "10.3748/wjg.v21.i43.12430",
language = "English (US)",
volume = "21",
pages = "12430--12438",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "43",

}

TY - JOUR

T1 - Re-re-treatment of hepatitis C virus

T2 - Eight patients who relapsed twice after direct-acting-antiviral drugs

AU - Hartman, Joshua

AU - Bichoupan, Kian

AU - Patel, Neal

AU - Chekuri, Sweta

AU - Harty, Alyson

AU - Dieterich, Douglas

AU - Perumalswami, Ponni

AU - Branch, Andrea D.

PY - 2015/11/21

Y1 - 2015/11/21

N2 - AIM: To determine risk factors associated with hepatitis C virus (HCV) treatment failure after direct acting antivirals in patients with complex treatment histories. METHODS: All HCV mono-infected patients who received treatment at our institution were queried. Analysis was restricted to patients who previously failed treatment with boceprevir (BOC) or telaprevir (TVR) and started simeprevir (SMV) and sofosbuvir (SOF) ± ribavirin (RBV) between December 2013 and June 2014. Patients with human immunodeficiency virus (HIV)/HCV co-infection or patients who received a liver transplant in the past were excluded. Viral loads were recorded while on treatment and after treatment. Data collection continued until December, 31st 2014 when data analysis was initiated. Patients missing virologic outcomes data were not included in the analysis. Analysis of 35 patients who had virologic outcome data available resulted in eight patients who were viral load negative at the end of treatment with SMF/SOF but later relapsed. Data related to patient demographics, HCV infection, and treatment history was collected in order to identify risk factors shared among patients who failed treatment with SMF/SOF. RESULTS: Eight patients who were treated with the first generation HCV protease inhibitors BOC or TVR in combination with pegylated-interferon (PEG) and RBV who failed this triple therapy were subsequently retreated with an off-label all-oral regimen of SMV and SOF for 12 wk, with RBV in seven cases. Treatment was initiated before the Food and Drug Administration approved a 24-wk SMV/SOF regimen for patients with liver cirrhosis. All eight patients had an end of treatment response, but later relapsed. Eight (100%) patients were male. Mean age was 56 (range, 49-64). Eight (100%) patients had previously failed PEG/ RBV dual therapy at least once in addition to prior failure with triple therapy. Total number of times treated ranged from 3-6 (mean 3.8). Eight (100%) patients were male had liver cirrhosis as determined by Fibroscan or MRI. Seven (87.5%) patients had genotype 1a HCV. Seven (87.5%) patients had over 1 million IU/mL HCV RNA at the time of re-treatment. CONCLUSION: This study identifies factors associated with SMV/SOF treatment failure and provides evidence that twleve weeks of SMV/SOF/RBV is insufficient in cirrhotics with high-titer genotype 1a HCV.

AB - AIM: To determine risk factors associated with hepatitis C virus (HCV) treatment failure after direct acting antivirals in patients with complex treatment histories. METHODS: All HCV mono-infected patients who received treatment at our institution were queried. Analysis was restricted to patients who previously failed treatment with boceprevir (BOC) or telaprevir (TVR) and started simeprevir (SMV) and sofosbuvir (SOF) ± ribavirin (RBV) between December 2013 and June 2014. Patients with human immunodeficiency virus (HIV)/HCV co-infection or patients who received a liver transplant in the past were excluded. Viral loads were recorded while on treatment and after treatment. Data collection continued until December, 31st 2014 when data analysis was initiated. Patients missing virologic outcomes data were not included in the analysis. Analysis of 35 patients who had virologic outcome data available resulted in eight patients who were viral load negative at the end of treatment with SMF/SOF but later relapsed. Data related to patient demographics, HCV infection, and treatment history was collected in order to identify risk factors shared among patients who failed treatment with SMF/SOF. RESULTS: Eight patients who were treated with the first generation HCV protease inhibitors BOC or TVR in combination with pegylated-interferon (PEG) and RBV who failed this triple therapy were subsequently retreated with an off-label all-oral regimen of SMV and SOF for 12 wk, with RBV in seven cases. Treatment was initiated before the Food and Drug Administration approved a 24-wk SMV/SOF regimen for patients with liver cirrhosis. All eight patients had an end of treatment response, but later relapsed. Eight (100%) patients were male. Mean age was 56 (range, 49-64). Eight (100%) patients had previously failed PEG/ RBV dual therapy at least once in addition to prior failure with triple therapy. Total number of times treated ranged from 3-6 (mean 3.8). Eight (100%) patients were male had liver cirrhosis as determined by Fibroscan or MRI. Seven (87.5%) patients had genotype 1a HCV. Seven (87.5%) patients had over 1 million IU/mL HCV RNA at the time of re-treatment. CONCLUSION: This study identifies factors associated with SMV/SOF treatment failure and provides evidence that twleve weeks of SMV/SOF/RBV is insufficient in cirrhotics with high-titer genotype 1a HCV.

KW - Hepatitis c

KW - Protease inhibitor

KW - Relapse

KW - Simeprevir

KW - Sofosbuvir

KW - Treatment failure

UR - http://www.scopus.com/inward/record.url?scp=84949033790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949033790&partnerID=8YFLogxK

U2 - 10.3748/wjg.v21.i43.12430

DO - 10.3748/wjg.v21.i43.12430

M3 - Article

VL - 21

SP - 12430

EP - 12438

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 43

ER -